Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  London, Cheryl A ^a   Bear, Misty D ^a   McCleese, Jennifer ^a   Foley, Kevin P ^b   Paalangara, Reji ^c   Inoue, Takayo ^d   Ying, Weiwen ^d   Barsoum, James ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Synta Pharmaceuticals Corp   (United States)

^e Theracrine Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BIOLOGICAL MARKER; CASPASE 3; CASPASE 7; FAMOTIDINE; GANETESPIB; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90 INHIBITOR; LOPERAMIDE; MAROPITANT; METOCLOPRAMIDE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PREDNISONE; PRODRUG; STA 1474; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; STA-1474; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOG; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; FEMALE; GASTROINTESTINAL TOXICITY; IN VITRO STUDY; LETHARGY; MALE; MASTOCYTOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OSTEOSARCOMA; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; THYROID CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UPREGULATION; VOMITING; ANIMAL; ANIMAL DISEASE; CHEMISTRY; DRUG ANTAGONISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NEOPLASM; TANDEM MASS SPECTROMETRY;

ANIMALIA; CANIS FAMILIARIS; MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; MALE; NEOPLASMS; PRODRUGS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 80455174301     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027018     Document Type: Article

References (38)

1. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
2. Wandinger SK, Richter K, Buchner J, (2008) The Hsp90 chaperone machinery. J Biol Chem 283: 18473-18477.
3. Whitesell L, Lindquist SL, (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772.
4. Zhao R, Houry WA, (2005) Hsp90: a chaperone for protein folding and gene regulation. Biochem Cell Biol 83: 703-710.
5. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
6. Pearl LH, Prodromou C, Workman P, (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410: 439-453.
7. Pratt WB, Toft DO, (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111-133.
8. Workman P, Burrows F, Neckers L, Rosen N, (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113: 202-216.
9. Xu W, Neckers L, (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13: 1625-1629.
10. Neckers L, Neckers K, (2005) Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics- an update. Expert Opin Emerg Drugs 10: 137-149.
11. Vastag B, (2006) HSP-90 inhibitors promise to complement cancer therapies. Nat Biotechnol 24: 1307.
12. Powers MV, Workman P, (2006) Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13 (Suppl 1): S125-135.
13. Bansal H, Bansal S, Rao M, Foley KP, Sang J, et al. (2010) Heat shock protein 90 regulates the expression of Wilms' tumor 1 protein in myeloid leukemias. Blood.
14. Lin TY, Bear M, Du Z, Foley KP, Ying W, et al. (2008) The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and-independent malignant mast cell tumors. Exp Hematol 36: 1266-1277.
15. McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, et al. (2009) The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 125: 2792-2801.
16. Veterinary Co-operative Oncology Group- Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2: 195-213.
17. Tsuchida Y, Therasse P, (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37: 1-3.
18. Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, et al. (2009) An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 15: 31-38.
19. Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, et al. (2008) Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br J Haematol 141: 483-493.
20. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, et al. (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1{alpha} autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13: 6459-6468.
21. Williams CR, Tabios R, Linehan WM, Neckers L, (2007) Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 178: 1528-1532.
22. Yano M, Naito Z, Tanaka S, Asano G, (1996) Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 87: 908-915.
23. Erlichman C, (2009) Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs 18: 861-868.
24. Gray PJ Jr, Stevenson MA, Calderwood SK, (2007) Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 67: 11942-11950.
25. Holmes JL, Sharp SY, Hobbs S, Workman P, (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 68: 1188-1197.
26. McDowell CL, Bryan Sutton R, Obermann WM, (2009) Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int J Biol Macromol 45: 310-314.
27. Kang BH, Plescia J, Song HY, Meli M, Colombo G, et al. (2009) Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 119: 454-464.
28. Leav I, Plescia J, Goel HL, Li J, Jiang Z, et al. (2010) Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 176: 393-401.
29. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, et al. (2003) Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs wtih spontaneous malignancies. Clin Cancer Res 9: 2755-2768.
30. McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C, (2006) Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 66: 10967-10975.
31. Powers MV, Clarke PA, Workman P, (2008) Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14: 250-262.
32. Beere HM, (2001) Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. Sci STKE 2001.
33. Mueller F, Fuchs B, Kaser-Hotz B, (2007) Comparative biology of human and canine osteosarcoma. Anticancer Res 27: 155-164.
34. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, et al. (2009) Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10: 625.
35. Chun R, de Lorimier LP, (2003) Update on the biology and management of canine osteosarcoma. Vet Clin North Am Small Anim Pract33: 491-516.
36. Clark JC, Dass CR, Choong PF, (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134: 281-297.
37. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV, (2011) Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2: 209-221.
38. Beloueche-Babari M, Arunan V, Jackson LE, Perusinghe N, Sharp SY, et al. (2010) Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget 1: 185-197.